You only have to look at the odd lots that are hitting the bid today to see how "someone" wants to paint the tape to the negative.(30 shares at .4125 and 145 shares at .4) Now, this is only possible because of the total lack of attention stock and company gets from the street.
Gtree at another closing high with big volume, and our forced low volume ugliness...........this disconnect will not continue much longer. Gtree's investors are the mirror image of rgrx's investors; yet their success depends on the exact same thing. So, millions of won (dollars) are buying gtree and seeing sure success in trials, while 58 dollars worth of stock is sold betting on failure. Its all very clear, ignore the ridiculous short term trading here and follow the real money(Gtree)
Teach, you cant be serious. Is this your first biotech? .
Why post things when you have no basis in fact. Did you see the #;s i gave you for shires drug. Does that make any sense to you? Why do you seek to inject a baseless worry?
I cant figure out 1/2 the posters rational here. Incredible
Come on teach. I dont mean to sound dismissive, but thats for a VACCINE. Those trials are notoriously large because of the potential harm they can do to the "healthy" population. Apples and Oranges.
JJ's strong statements below. Now, lets here why sno doesnt like this press release.........
Completion of enrollment for the dry eye study marks a key milestone. Treatment and patient follow-up should be completed in February with data analysis shortly thereafter. Everyone involved in the study is looking forward to the efficacy analysis and toward commercial development of RGN-259 for this underserved market. Positive results should also have a significant impact in the development cycle for our product candidate in Asia, Europe, and other markets throughout the world, as well as in its development for other ocular indications," stated J.J. Finkelstein, RegeneRx's president and chief executive officer.
7 to 10 thousand? Where do you come up with that number? If you look at the Lifitegrast trials in P3, they did and Opus1 with 588 patients, and Opus 2 with 718 patients, and a Sonata safety trial (which had plenty of adverse reactions) with 300 patients. And they are about to get approval.
Given the fact that TB4 has been used on 1000's of patients for various indications and shown no safety problems, your number is way to high.
I would guess enough gtree stock to give us an immediate 100 to 150 mil marketcap. The low end would be a double and those still wanting to stick around could just take gtree stock and ride the korean market and trial success. Dont see a downside if koreans are super aggressive. Many inflated US bio's grew larger through roll ups.
ST's blessing. Goldstein and JJ will go with it as they would still own the TB4 franchise with gtree stock. And, gtree have confidence in trials. The most important time to make offer is when difference in market cap is at its widest. IMHO
Selloff taking rgrx down to lower end of trading range, while gtree makes new high. That is exactly what a buyer(gtree) would want to see if an offer of gtree stock is about to be announced to rgrx holders.
The wider the spread the more attractive deal would look.
This stock is so played. Buy'em if you can.
Good luck with the vegas money."Why should it?" Almost a 400 million dollar market cap on a foreign company that only has TB4 in its pipeline. The same company that is seeing early data on the trials. I guess you must think the Koreans are either some kind of scam artist or some kind of stupid.
Problem is that the few investors here have seen nothing but failures from management. So, not surprising all are expecting the worst. The flaw in that logic is that current management has little to do with what is happening now. The Koreans are running the show...........thats the bet. Soon we all will be owning Gtree shares
Hey mia, as one of the long time longs, what is your feeling about Gtree's valuation? Does it give you any confidence in the success of one or both of the on going trials? Or do you think its just an unrelated Korean valuation?
And you did make a comment last time about spending some vegas money here. Hows that going? Waiting on a selloff?
Sno, stick to your research. You are clueless and clearly have no experience with bio's to make such a silly statement. The PR release was just fine and no additional hype was needed for those who might be interested in data.
Gtree is not a private company. So no, not a reverse merger; just a cross border acquisition. Let the lawyers figure out where domiciled. But, gtree has big ambitions, and to get a US listing(go to OTC after) would be something for a near BK software company not long ago. They would be the first korean biotech to do so.
Gtree stock price allows them much leverage here. They could have never gotten the whole TB4 franchise when they originally cut the JV deal. No matter how much they might have wanted to. But now, with that currency, they could easily get all of RGRX. How aggressive are they? We will find out soon